id CRUZ_d60531d397cb35db49d6526986642233
oai_identifier_str oai:www.arca.fiocruz.br:icict/5794
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Romanha, Álvaro JoséCastro, Solange Lisboa deSoeiro, Maria de Nazaré CorreiaVieira, Joseli LannesRibeiro, IsabelaTalvani, AndréBourdin, BernadetteBlum, BethaniaOlivieri, BiancaZani, Carlos LeomarSpadafora, CarmenzaChiari, ÉglerChatelain, EricChaves, GabrielaCalzada, José EduardoBustamante, Juan ManuelFreitas Junior, Lucio Holanda Gondim deRomero, Luz I.Bahia, Maria TerezinhaLotrowska, MichelSoares, Milena Botelho PereiraAndrade, Sonia GumesArmstrong, TanyaDegrave, WimAndrade, Zilton de Araújo2012-11-12T19:20:36Z20122010ROMANHA, Alvaro et al. In vitro and in vivo experimental models for drug screening and development for Chagas disease. Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 105(2): 233-238, March 20100074-0276https://www.arca.fiocruz.br/handle/icict/5794Fiocruz, DNDiFundação Oswaldo Cruz. Instituto Oswaldo Cruz. Programa Integrado de Doença de Chagas. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisas René Rachou. Belo Horizonte, MG, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Programa Integrado de Doença de Chagas. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Programa Integrado de Doença de Chagas. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Programa Integrado de Doença de Chagas. Rio de Janeiro, RJ, Brasil/Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.Drugs for Neglected Disease Initiative.Geneva, SwitzerlandUniversidade Federal de Ouro Preto. Departamento de Ciências Biológicas. Ouro Preto, MG, Brasil.Drugs for Neglected Disease Initiative. Geneva, Switzerland.Drugs for Neglected Disease Initiative, Geneva, Switzerland.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Programa Integrado de Doença de Chagas. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Programa Integrado de Doença de Chagas. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisas René Rachou. Belo Horizonte, MG, Brasil.Instituto de Investigaciones Científicas y Servicios de Alta Tecnologia- AIP. Clayton, Panamá.Universidade Federal de Minas Gerais. Belo Horizonte, MG, Brasil.Drugs for Neglected Disease Initiative.Geneva, SwitzerlandMédecins sans Frontières. Geneva, Switzerland.Instituto Conmemorativo Gorgas de Estudios de la Salud. Panamá, Panamá.University of Georgia. Center for Tropical and Emerging Global Disease. GA, USA..Institute Pasteur-Korea. Center for Neglected Diseases Drug Discovery. Gyeonggi-do, Korea.Instituto de Investigaciones Científicas y Servicios de Alta Tecnologia-AIP. Clayton, Panamá.Universidade Federal de Ouro Preto. Departamento de Ciências Biológicas. Ouro Preto, MG, Brasil.Drugs for Neglected Disease Initiative. Geneva, Switzerland.Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Programa Integrado de Doença de Chagas. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil.Murdoch University. Murdoch, AustráliaPrograma Integrado de Doença de Chagas. Rio de Janeiro, RJ, Brasil / Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Programa Integrado de Doença de Chagas. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil.Chagas disease, a neglected illness, affects nearly 12-14 million people in endemic areas of Latin America. Al¬though the occurrence of acute cases sharply has declined due to Southern Cone Initiative efforts to control vector transmission, there still remain serious challenges, including the maintenance of sustainable public policies for Chagas disease control and the urgent need for better drugs to treat chagasic patients. Since the introduction of benznidazole and nifurtimox approximately 40 years ago, many natural and synthetic compounds have been as¬sayed against Trypanosoma cruzi, yet only a few compounds have advanced to clinical trials. This reflects, at least in part, the lack of consensus regarding appropriate in vitro and in vivo screening protocols as well as the lack of biomarkers for treating parasitaemia. The development of more effective drugs requires (i) the identification and validation of parasite targets, (ii) compounds to be screened against the targets or the whole parasite and (iii) a panel of minimum standardised procedures to advance leading compounds to clinical trials. This third aim was the topic of the workshop entitled Experimental Models in Drug Screening and Development for Chagas Disease, held in Rio de Janeiro, Brazil, on the 25th and 26th of November 2008 by the Fiocruz Program for Research and Technological Development on Chagas Disease and Drugs for Neglected Diseases Initiative. During the meeting, the minimum steps, requirements and decision gates for the determination of the efficacy of novel drugs for T. cruzi control were evaluated by interdisciplinary experts and an in vitro and in vivo flowchart was designed to serve as a general and standardised protocol for screening potential drugs for the treatment of Chagas disease.engInstituto Oswaldo CruzIn vitro and in vivo experimental models for drug screening and development for Chagas diseaseinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleTrypanosoma cruziChagas disease treatmentdrug screeningbenznidazoleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZORIGINAL100.2010.pdf100.2010.pdfapplication/pdf628329https://www.arca.fiocruz.br/bitstream/icict/5794/1/100.2010.pdfe376150db1b041e55dd80e513a9798f8MD51TEXT100.2010.pdf.txt100.2010.pdf.txtExtracted texttext/plain36120https://www.arca.fiocruz.br/bitstream/icict/5794/4/100.2010.pdf.txt96b23f6b75d052e80cf4166c19466f2bMD54THUMBNAIL100.2010.pdf.jpg100.2010.pdf.jpgGenerated Thumbnailimage/jpeg2263https://www.arca.fiocruz.br/bitstream/icict/5794/3/100.2010.pdf.jpg40d2de8f36d962bbe4afca3b0ea54bcfMD53icict/57942023-09-05 10:30:54.912oai:www.arca.fiocruz.br:icict/5794Repositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-09-05T13:30:54Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv In vitro and in vivo experimental models for drug screening and development for Chagas disease
title In vitro and in vivo experimental models for drug screening and development for Chagas disease
spellingShingle In vitro and in vivo experimental models for drug screening and development for Chagas disease
Romanha, Álvaro José
Trypanosoma cruzi
Chagas disease treatment
drug screening
benznidazole
title_short In vitro and in vivo experimental models for drug screening and development for Chagas disease
title_full In vitro and in vivo experimental models for drug screening and development for Chagas disease
title_fullStr In vitro and in vivo experimental models for drug screening and development for Chagas disease
title_full_unstemmed In vitro and in vivo experimental models for drug screening and development for Chagas disease
title_sort In vitro and in vivo experimental models for drug screening and development for Chagas disease
author Romanha, Álvaro José
author_facet Romanha, Álvaro José
Castro, Solange Lisboa de
Soeiro, Maria de Nazaré Correia
Vieira, Joseli Lannes
Ribeiro, Isabela
Talvani, André
Bourdin, Bernadette
Blum, Bethania
Olivieri, Bianca
Zani, Carlos Leomar
Spadafora, Carmenza
Chiari, Égler
Chatelain, Eric
Chaves, Gabriela
Calzada, José Eduardo
Bustamante, Juan Manuel
Freitas Junior, Lucio Holanda Gondim de
Romero, Luz I.
Bahia, Maria Terezinha
Lotrowska, Michel
Soares, Milena Botelho Pereira
Andrade, Sonia Gumes
Armstrong, Tanya
Degrave, Wim
Andrade, Zilton de Araújo
author_role author
author2 Castro, Solange Lisboa de
Soeiro, Maria de Nazaré Correia
Vieira, Joseli Lannes
Ribeiro, Isabela
Talvani, André
Bourdin, Bernadette
Blum, Bethania
Olivieri, Bianca
Zani, Carlos Leomar
Spadafora, Carmenza
Chiari, Égler
Chatelain, Eric
Chaves, Gabriela
Calzada, José Eduardo
Bustamante, Juan Manuel
Freitas Junior, Lucio Holanda Gondim de
Romero, Luz I.
Bahia, Maria Terezinha
Lotrowska, Michel
Soares, Milena Botelho Pereira
Andrade, Sonia Gumes
Armstrong, Tanya
Degrave, Wim
Andrade, Zilton de Araújo
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Romanha, Álvaro José
Castro, Solange Lisboa de
Soeiro, Maria de Nazaré Correia
Vieira, Joseli Lannes
Ribeiro, Isabela
Talvani, André
Bourdin, Bernadette
Blum, Bethania
Olivieri, Bianca
Zani, Carlos Leomar
Spadafora, Carmenza
Chiari, Égler
Chatelain, Eric
Chaves, Gabriela
Calzada, José Eduardo
Bustamante, Juan Manuel
Freitas Junior, Lucio Holanda Gondim de
Romero, Luz I.
Bahia, Maria Terezinha
Lotrowska, Michel
Soares, Milena Botelho Pereira
Andrade, Sonia Gumes
Armstrong, Tanya
Degrave, Wim
Andrade, Zilton de Araújo
dc.subject.en.pt_BR.fl_str_mv Trypanosoma cruzi
Chagas disease treatment
drug screening
benznidazole
topic Trypanosoma cruzi
Chagas disease treatment
drug screening
benznidazole
description Fiocruz, DNDi
publishDate 2010
dc.date.issued.fl_str_mv 2010
dc.date.accessioned.fl_str_mv 2012-11-12T19:20:36Z
dc.date.available.fl_str_mv 2012
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv ROMANHA, Alvaro et al. In vitro and in vivo experimental models for drug screening and development for Chagas disease. Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 105(2): 233-238, March 2010
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/5794
dc.identifier.issn.none.fl_str_mv 0074-0276
identifier_str_mv ROMANHA, Alvaro et al. In vitro and in vivo experimental models for drug screening and development for Chagas disease. Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 105(2): 233-238, March 2010
0074-0276
url https://www.arca.fiocruz.br/handle/icict/5794
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Instituto Oswaldo Cruz
publisher.none.fl_str_mv Instituto Oswaldo Cruz
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/5794/1/100.2010.pdf
https://www.arca.fiocruz.br/bitstream/icict/5794/4/100.2010.pdf.txt
https://www.arca.fiocruz.br/bitstream/icict/5794/3/100.2010.pdf.jpg
bitstream.checksum.fl_str_mv e376150db1b041e55dd80e513a9798f8
96b23f6b75d052e80cf4166c19466f2b
40d2de8f36d962bbe4afca3b0ea54bcf
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1798325091405135872